— Know what they know.
Not Investment Advice

ULGX OTC

Urologix, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -0.0% 5Y: -97.3%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Devices · Tech Score Neutral · Power 52 · $2182 mcap · 21M float · 0.0058% daily turnover · Short 50% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000099999997-0.0126
Volume125
Avg Volume1,202
Beta-0.77
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOBryon Merade
Employees61
SectorHealthcare
IndustryMedical - Devices
IPO Date1996-05-30
14405 21st Avenue North
Minneapolis, MN 55447
US
763 475 1400
About Urologix, Inc.

Established in 1991 and headquartered in Minneapolis, Minnesota, Urologix, Inc. specializes in the development, production, promotion, and distribution of minimally invasive medical devices across the United States. The company's innovative solutions target the treatment of obstructions and related symptoms caused by benign prostatic hyperplasia (BPH). Among its key offerings is Cooled ThermoTherapy, a system that precisely applies microwave energy while simultaneously employing a cooling mechanism to safeguard healthy tissues and improve patient comfort. Urologix also provides the Prostiva RF Therapy System, which directs radio frequency energy into the prostate gland. This process works to eliminate problematic prostatic tissue, consequently easing urethral constriction and alleviating BPH-related discomfort. Urologix, Inc. caters to both healthcare professionals and patients.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
EMERY SIDNEY W JR S-Sale 10,000 $0.09 2014-11-20
EMERY SIDNEY W JR S-Sale 10,000 $0.09 2014-11-19
EMERY SIDNEY W JR A-Award 45,455 — 2014-11-06
EMERY SIDNEY W JR A-Award 50,000 — 2013-11-07
EMERY SIDNEY W JR A-Award 26,516 — 2012-11-16

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms